Cardiothoracic & vascular anesthesia
Cytokine Hemoadsorption versus Standard Care in Cardiac Surgery Using the Oxiris Membrane: The OXICARD Single-center Randomized Trial
Primary result · Oxiris minus standardResult — go to the resultDifference −0.17 95% CI −0.44 to 0.10Authors' conclusion
In patients scheduled for a cardiac surgery with prolonged CPB, the authors could not demonstrate the benefit on microcirculation and major cardiovascular events.
Study context
- Population
- Adults admitted for scheduled cardiac surgery with expected cardiopulmonary bypass (CPB) time >90 min2 excluded from Oxiris group
- Participants
- 70 adults
- Comparison
- Oxiris membrane hemoadsorption during CPB vs standard care
- Primary endpoint
- Sublingual microcirculation by microvascular flow index (graded 0 to 3; 0 no flow, 3 continuous flow), change from baseline
- Follow-up
- Day 1 after surgery
Methodological detailssingle-centre, October 2019 to November 2022, Amiens University Hospital (France)
- Single-centre
- October 2019 to November 2022, Amiens University Hospital (France)
Primary result
Oxiris minus standard
Difference
−0.17
95% CI −0.44 to 0.10
P = 0.2
Oxiris vs Standard
difference −0.17 (95% CI −0.44 to 0.10); P = 0.2
As reported in the abstract
Secondary outcomes
Composite adverse outcome · within 30 days after surgery
P = 0.7
Cytokines and angiopoietins
- Overall variation did not significantly differ between groups
Original publication
Cytokine Hemoadsorption versus Standard Care in Cardiac Surgery Using the Oxiris Membrane: The OXICARD Single-center Randomized Trial. Anesthesiology. Published 21 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →